Title Prevalence and clinical correlates of YMDD variants duringlamivudine therapy for patients with chronic hepatitis B

[1]  R. Ebrahimi,et al.  Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis , 2002 .

[2]  M. Buti,et al.  Three years of lamivudine in anti-HBe positive patients decreased virological and biochemical response , 2002 .

[3]  M. Manns,et al.  Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.

[4]  P. Marcellin,et al.  GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. , 2001 .

[5]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[6]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[7]  M. Buti,et al.  Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. , 2001, The Journal of infectious diseases.

[8]  J. Petersen,et al.  20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw , 2001, The Lancet.

[9]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[10]  E. Schiff,et al.  A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.

[11]  R. D. de Man,et al.  Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.

[12]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[13]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[14]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[15]  D. Pillay,et al.  Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient , 2000, Gut.

[16]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[17]  C. Hannoun,et al.  Long-term mutation rates in the hepatitis B virus genome. , 2000, The Journal of general virology.

[18]  J. Dienstag,et al.  Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. , 1999, The Journal of infectious diseases.

[19]  F. Zoulim.  Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. , 1999, Antiviral research.

[20]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[21]  E. Schiff,et al.  Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy , 1999, Hepatology.

[22]  F. Baldanti,et al.  Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine , 1999, Journal of Clinical Microbiology.

[23]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[24]  M. Manns,et al.  Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation , 1999, Hepatology.

[25]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[26]  T. Harrison,et al.  Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. , 1999, The Journal of general virology.

[27]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[28]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[29]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[30]  E. Schiff,et al.  A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy , 1998 .

[31]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[32]  D. Kimberlin,et al.  Antiviral resistance: mechanisms, clinical significance, and future implications. , 1996, The Journal of antimicrobial chemotherapy.

[33]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[34]  U. Akarca,et al.  Naturally occurring hepatitis B virus core gene mutations , 1995, Hepatology.

[35]  J. Sninsky,et al.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.

[36]  H. Blum.  Variants of hepatitis B, C and D viruses: molecular biology and clinical significance. , 1995, Digestion.

[37]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[38]  N. Lurain,et al.  A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. , 1992, The Journal of infectious diseases.

[39]  A. Erice,et al.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir , 1991 .

[40]  O. Laskin,et al.  ISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY , 1982, The Lancet.